Company intelligence / Profile preview
Chengdu Youluo Biotechnology Co., Ltd.
Chengdu, Sichuan, Chinayoulum.com.tw ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Chengdu Youluo Biotechnology Co., Ltd. focuses on the development of monoclonal antibodies and nanobodies targeting neoplasms and nervous system diseases. Its lead asset, EP‑9001A targeting NGF for cancer pain, has reached Phase 2 clinical trials as of May 2025. The company also has two additional discovery-stage programs.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Monoclonal antibodyNanobody
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Chengdu Youluo Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Youluo Biotechnology Co., Ltd..